OA
MCID: OST012
MIFTS: 80

Osteoarthritis (OA)

Categories: Bone diseases, Muscle diseases

Aliases & Classifications for Osteoarthritis

MalaCards integrated aliases for Osteoarthritis:

Name: Osteoarthritis 12 75 25 29 55 6 43 3 44 15 38 63 40 17
Osteoarthrosis 12 25 15
Degenerative Joint Disease 12 25
Degenerative Polyarthritis 25 72
Hypertrophic Arthritis 12 25
Arthropathy 25 72
Osteoarthrosis and Allied Disorder 12
Osteoarthritis Deformans 25
Osteoarthrosis Deformans 72
Arthritis, Degenerative 25
Degenerative Arthritis 12
Kashin-Beck Disease 72
Oa 25

Characteristics:


Classifications:



External Ids:

Disease Ontology 12 DOID:8398
ICD9CM 35 715.3
MeSH 44 D010003
UMLS 72 C0022408 C0029408 C0086743 more

Summaries for Osteoarthritis

Genetics Home Reference : 25 Osteoarthritis is a common disease of the joints that primarily occurs in older adults. This condition is characterized by the breakdown of cartilage, the tough but flexible tissue that covers the ends of the bones at the joints and allows smooth joint movements. One or more parts of the body can be affected, most often the hands, shoulders, spine, knees, or hips. Osteoarthritis usually develops slowly, causing pain, stiffness, and restricted movement as the condition gets worse. Areas of bone no longer cushioned by cartilage rub against each other and start to break down. Further damage is caused as the body attempts to repair and rebuild these tissues. The immune system, which plays a role in healing injuries, targets these areas, and its response leads to inflammation of the joint tissues. Abnormal growths of bone (osteophytes) and other tissue can also occur, and may be visible as enlarged joints. Enlargement of the joints of the fingers is especially noticeable. People with osteoarthritis typically experience stiffness following periods of inactivity such as upon awakening or rising from a chair; the stiffness usually improves as they move around. In some affected individuals, the condition never causes major problems. In others, severe osteoarthritis can impair mobility and the ability to perform daily tasks, affecting quality of life and increasing the risk of other health conditions such as cardiovascular disease. Osteoarthritis is most common in middle age or late adulthood, because the cartilage at the joints naturally begins to thin as people age. However, it can occur earlier in life, especially after injuries affecting the joints such as a type of knee injury called an anterior cruciate ligament (ACL) tear. People who are overweight or whose activities are particularly stressful to the joints are also at increased risk of developing osteoarthritis.

MalaCards based summary : Osteoarthritis, also known as osteoarthrosis, is related to pseudoachondroplasia and cartilage disease, and has symptoms including tremor, joint stiffness and arthralgia. An important gene associated with Osteoarthritis is FRZB (Frizzled Related Protein), and among its related pathways/superpathways are Degradation of the extracellular matrix and Endochondral Ossification. The drugs Spironolactone and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include Cartilage and Bone, and related phenotypes are abnormality of pelvic girdle bone morphology and hip osteoarthritis

Disease Ontology : 12 An arthritis that has material basis in worn out cartilage located in joint.

MedlinePlus : 43 Osteoarthritis is the most common form of arthritis. It causes pain, swelling, and reduced motion in your joints. It can occur in any joint, but usually it affects your hands, knees, hips or spine. Osteoarthritis breaks down the cartilage in your joints. Cartilage is the slippery tissue that covers the ends of bones in a joint. Healthy cartilage absorbs the shock of movement. When you lose cartilage, your bones rub together. Over time, this rubbing can permanently damage the joint. Risk factors for osteoarthritis include Being overweight Getting older Injuring a joint No single test can diagnose osteoarthritis. Most doctors use several methods, including medical history, a physical exam, x-rays, or lab tests. Treatments include exercise, medicines, and sometimes surgery. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

CDC : 3 Osteoarthritis (OA) is the most common form of arthritis. Some people call it degenerative joint disease or "wear and tear" arthritis. It occurs most frequently in the hands, hips, and knees. With OA, the cartilage within a joint begins to break down and the underlying bone begins to change. These changes usually develop slowly and get worse over time. OA can cause pain, stiffness, and swelling. In some cases it also causes reduced function and disability; some people are no longer able to do daily tasks or work.

PubMed Health : 63 About osteoarthritis: Painful or stiff joints and a crunching sensation in the joints are typical signs of osteoarthritis, often also called "degenerative joint disease." Lots of people have joint problems as they get older, and some already have problems in middle age. If symptoms get worse, they can severely limit mobility. Osteoarthritis can affect every joint, but it is most common in the knee, hip or spine.

Wikipedia : 75 Osteoarthritis (OA) is a type of joint disease that results from breakdown of joint cartilage and... more...

Related Diseases for Osteoarthritis

Diseases related to Osteoarthritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1187)
# Related Disease Score Top Affiliating Genes
1 pseudoachondroplasia 33.5 MATN3 COMP ACAN
2 cartilage disease 33.3 COMP COL2A1 ACAN
3 epiphyseal dysplasia, multiple, 1 33.0 MATN3 COMP ACAN
4 epiphyseal dysplasia, multiple, 5 32.7 MATN3 COMP
5 transient arthritis 31.8 COMP ACAN
6 degenerative disc disease 31.5 GDF5 ASPN ACAN
7 osteochondritis dissecans 31.4 MMP13 MATN3 COMP ACAN
8 bone disease 31.4 MMP13 GDF5 COL2A1 ACAN
9 multiple epiphyseal dysplasia 31.3 MATN3 COMP COL2A1 ACAN
10 bone inflammation disease 31.2 MMP13 COMP COL2A1 ACAN
11 coxa vara 31.1 MMP13 COL2A1
12 spondyloepiphyseal dysplasia congenita 31.1 MMP13 COMP COL2A1 ASPN
13 skeletal dysplasias 31.0 MATN3 COMP COL2A1
14 brachydactyly 30.9 GDF5 COMP COL2A1
15 kniest dysplasia 30.6 COMP COL2A1 ASPN
16 bone chondrosarcoma 30.6 MMP13 COMP ACAN
17 hypochondrogenesis 30.5 COMP COL2A1 ASPN ACAN
18 spondyloepimetaphyseal dysplasia, matrilin-3 related 30.3 MATN3 COL2A1
19 pituitary adenoma 29.6 MEG3 HOTAIR H19
20 malignant glioma 29.4 PCGEM1 HOTAIR GAS5
21 myeloma, multiple 29.3 MEG3 HOTAIR H19 GAS5
22 lung cancer susceptibility 3 29.0 MEG3 HOTAIR H19 GAS5
23 glioblastoma 28.9 MEG3 HOTAIR H19 GAS5
24 osteogenic sarcoma 28.4 PACERR MEG3 HOTAIR H19 GAS5
25 hepatocellular carcinoma 27.0 UFC1 MEG3 KCTD13 HOTAIR H19 GAS5
26 multicentric osteolysis, nodulosis, and arthropathy 12.7
27 arthropathy, progressive pseudorheumatoid, of childhood 12.7
28 short stature and advanced bone age, with or without early-onset osteoarthritis and/or osteochondritis dissecans 12.7
29 osteoarthritis with mild chondrodysplasia 12.7
30 behcet's syndrome arthropathy 12.3
31 arthropathy, erosive 12.3
32 loeys-dietz syndrome 3 12.3
33 transient arthropathy 12.3
34 multicentric osteolysis-nodulosis-arthropathy spectrum 12.3
35 obsolete: progeria-associated arthropathy 12.1
36 chondrocalcinosis 2 12.1
37 myhre syndrome 12.1
38 familial osteochondritis dissecans 12.1
39 czech dysplasia 12.0
40 chondrocalcinosis 1 11.8
41 esophageal atresia 11.8
42 beukes hip dysplasia 11.7
43 jaccoud's syndrome 11.7
44 mitochondrial dna depletion syndrome 6 11.7
45 microphthalmia with limb anomalies 11.6
46 otospondylomegaepiphyseal dysplasia, autosomal recessive 11.6
47 rheumatoid arthritis 11.6
48 hemochromatosis, type 2a 11.6
49 spondylosis 11.5
50 arthritis 11.5

Comorbidity relations with Osteoarthritis via Phenotypic Disease Network (PDN): (show all 23)


Active Peptic Ulcer Disease Acute Cystitis
Anxiety Benign Essential Hypertension
Bronchitis Decubitus Ulcer
Deficiency Anemia Dysthymic Disorder
Esophagitis First-Degree Atrioventricular Block
Generalized Atherosclerosis Gout
Heart Disease Hypertension, Essential
Hypothyroidism Intermediate Coronary Syndrome
Iron Deficiency Anemia Major Depressive Disorder
Osteoporosis Peripheral Vascular Disease
Rheumatoid Arthritis Schizophreniform Disorder
Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Osteoarthritis:



Diseases related to Osteoarthritis

Symptoms & Phenotypes for Osteoarthritis

Human phenotypes related to Osteoarthritis:

32
# Description HPO Frequency HPO Source Accession
1 abnormality of pelvic girdle bone morphology 32 HP:0002644
2 hip osteoarthritis 32 HP:0008843

UMLS symptoms related to Osteoarthritis:


tremor, joint stiffness, arthralgia, angina pectoris, back pain, sciatica, equilibration disorder, muscle cramp, metatarsalgia, joint symptom, musculoskeletal symptom, other symptoms referable to joint, stiffness of joint, not elsewhere classified in icd10cm, other symptoms referable to joint, shoulder region, other symptoms referable to joint, upper arm, other symptoms referable to joint, forearm, other symptoms referable to joint, hand, other symptoms referable to joint, pelvic region and thigh, other symptoms referable to joint, lower leg, other symptoms referable to joint, ankle and foot, other symptoms referable to joint, other specified sites, other symptoms referable to joint, multiple sites, other symptoms referable to joint, site unspecified

MGI Mouse Phenotypes related to Osteoarthritis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 limbs/digits/tail MP:0005371 9.1 COL2A1 COMP FRZB GDF5 MATN3 MMP13

Drugs & Therapeutics for Osteoarthritis

PubMed Health treatment related to Osteoarthritis: 63

There are many different suggestions and recommendations for treating osteoarthritis, but so far no cure. Most treatments aim to at least slow down the development of osteoarthritis and relieve the symptoms so that daily life is affected as little as possible. There are two different types of therapies: Surgical and non-surgical. Non-surgical therapies include painkillers, exercise and weight loss, for example. Obese people with osteoarthritis of the knee or hip are often advised to lose weight. Studies indicate that weight loss can be helpful if it is combined with exercise therapy. The question of which therapies can improve mobility and relieve pain also depends on the joint that is affected. For example, therapy involving aerobics or muscle-strengthening exercises could help people with knee osteoarthritis. Other treatment options include massage, acupuncture, TENS, medicinal baths or orthopedic insoles. Surgery options for osteoarthritis of the knee include smoothing the cartilage (arthroscopy). But in many cases people who have had an arthroscopy to smooth out their knee cartilage experience pain and difficulties just as often as those who do not have an operation. There are other surgical therapy options available for people with advanced osteoarthritis. For example, a knee or hip joint can be replaced fully or in part with an artificial joint (called an endoprosthesis).

DrugBank drugs 16 :

(show all 24)
# Drug Name Indication DrugBank ID
1 Bupivacaine For the production of local or regional anesthesia or analgesia for surgery, for oral surgery procedures, for diagnostic and therapeutic procedures, and for obstetrical procedures. DB00297
2 Celecoxib Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA).[L7646] Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.[L7586,L7646] It may be also be used to treat acute pain from various sources, juvenile rheumatoid arthritis in children over 2, ankylosing spondylitis, and primary dysmenorrhea. In addition, celecoxib is used as an adjunct to therapy for patients diagnosed with familial adenomatous polyposis.[L7646] DB00482
3 Choline magnesium trisalicylate Choline magnesium trisalicylate is used to reduce pain and inflammation caused by conditions such as arthritis. This medication is also used to treat fever in adults. DB01401
4 Diclofenac Diclofenac is indicated for use in the treatment of pain and inflammation from varying sources including inflammatory conditions such as osteoarthritis, rheumatoid arthritis, and akylosing spondylitis, as well as injury-related inflammation due to surgery and physical trauma. It is often used in combination with [misoprostol] as a gastro-protective agent in patients with high risk of developing NSAID-induced ulcers. DB00586
5 Diflunisal For symptomatic treatment of mild to moderate pain accompanied by inflammation (e.g. musculoskeletal trauma, post-dental extraction, post-episiotomy), osteoarthritis, and rheumatoid arthritis. DB00861
6 Duloxetine **Indicated** for: 1) Management of Major Depressive Disorder.[label] 2) Management of Generalized Anxiety Disorder.[label] 3) Management of diabetic peripheral neuropathy.[label] 4) Management of fibromyalgia.[label] 5) Management of chronic musculoskeletal pain.[label] 6) Management of osteoarthritis of the knee in adults.[L6364] 7) Management of chronic lower back pain in adults.[L6364] 8) Management of stress urinary incontinence in adult women.[L6367] **Off-label** uses include: 1) Management of chemotherapy-induced peripheral neuropathy.[A178603] 2) Management of stress urinary incontinence in adult men after prostatectomy until recovery is complete.[L6370] DB00476
7 Etodolac For acute and long-term management of signs and symptoms of osteoarthritis and rheumatoid arthritis, as well as for the management of pain. DB00749
8 Fenoprofen For relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Also for the relief of mild to moderate pain. DB00573
9 Flurbiprofen Flurbiprofen tablets are indicated for the acute or long-term symptomatic treatment of rheumatoid arthritis, osteorarthritis and anklosing spondylitis. It may also be used to treat pain associated with dysmenorrhea and mild to moderate pain accompanied by inflammation (e.g. bursitis, tendonitis, soft tissue trauma). Topical ophthalmic formulations may be used pre-operatively to prevent intraoperative miosis. DB00712
10 Ibuprofen Ibuprofen is the most commonly used and prescribed NSAID. It is very common over the counter medication widely used as an analgesic, anti-inflammatory and antipyretic.[A39096] The use of ibuprofen and its enantiomer [DB09213] in a racemic mix is common for the management of mild to moderate pain related to dysmenorrhea, headache, migraine, postoperative dental pain, spondylitis, osteoarthritis, rheumatoid arthritis, and soft tissue disorder.[A39097] Due to its activity against prostaglandin and thromboxane synthesis, ibuprofen has been attributed to alteration of platelet function and prolongation of gestation and labor.[A39092] As ibuprofen is a widely used medication, the main therapeutic indications are: * Patent Ductus Arteriosus - it is a neonatal condition wherein the ductus arteriosus (blood vessel that connects the main pulmonary artery to the proximal descending aorta) fails to close after birth causing severe risk of heart failure. The prostaglandin inhibition of ibuprofen has been studied for the treatment of this condition as it is known that prostaglandin E2 is responsible for keeping the ductus arteriosus open.[A39100] * Rheumatoid- and osteo-arthritis - ibuprofen is very commonly used in the symptomatic treatment of inflammatory, musculoskeletal and rheumatic disorders.[A39176] * Cystic fibrosis - the use of high dosages of ibuprofen has been proven to decrease inflammation and decreasing polymorphonuclear cell influx in the lungs.[A39177] * Orthostatic hypotension - ibuprofen can induce sodium retention and antagonize the effect of diuretics which has been reported to be beneficial for patients with severe orthostatic hypotension.[A1651] * Dental pain - ibuprofen is used to manage acute and chronic orofacial pain.[A10901] * Minor pain - ibuprofen is widely used to reduce minor aches and pains as well as to reduce fever and manage dysmenorrhea. It is very commonly used for the relief of acute indications such as fever and tension headaches.[A39092] * Investigational uses - efforts have been put into developing ibuprofen for the prophylaxis of Alzheimer's disease, Parkinson disease, and breast cancer.[A39092] DB01050
11 Indomethacin Oral indometacin is indicated for symptomatic management of moderate to severe rheumatoid arthritis including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis.[A177871,L6778] Intravenous indometacin is indicated to induce closure of a hemodynamically significant patent ductus arteriosus in premature infants weighing between 500 and 1750 g when after 48 hours usual medical management (e.g., fluid restriction, diuretics, digitalis, respiratory support, etc.) is ineffective.[F4600] DB00328
12 Ketoprofen For symptomatic treatment of acute and chronic rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, primary dysmenorrhea and mild to moderate pain associated with musculotendinous trauma (sprains and strains), postoperative (including dental surgery) or postpartum pain. DB01009
13 Meclofenamic acid For the relief of mild to moderate pain, for the treatment of primary dysmenorrhea and for the treatment of idiopathic heavy menstrual blood loss. Also for relief of the signs and symptoms of acute and chronic rheumatoid arthritis and osteoarthritis. DB00939
14 Meloxicam For symptomatic treatment of arthritis and osteoarthritis. DB00814
15 Nabumetone **Indicated** for:[label] 1) Symptomatic relief in rheumatoid arthritis. 2) Symptomatic relief in osteoarthritis. DB00461
16 Naproxen Naproxen is indicated for the management of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, tendinitis, bursitis, acute gout, primary dysmenorrhea, and for the relief of mild to moderate pain.[L6582][L6583][A178975] Further, it is first-line therapy for osteoarthritis, acute gouty arthritis, dysmenorrhea, and musculoskeletal inflammation and pain.[A178975] DB00788
17 Ox bile extract DB14016
18 Oxaprozin Used to relieve the inflammation, swelling, stiffness, and joint pain associated with rheumatoid arthritis and osteoarthritis. DB00991
19 Piroxicam For treatment of osteoarthritis and rheumatoid arthritis. DB00554
20 Ranitidine This drug is used alone or with concomitant antacids for the following conditions [FDA label]: **Duodenal ulcer** Treatment of active duodenal ulcer (short-term), maintenance therapy of duodenal ulcers after healing (reduced dose) **Pathological hypersecretion of gastric acid** Zollinger-Ellison syndrome, systemic mastocytosis, and other conditions causing gastric acid hypersecretion **Gastric ulcer** Short term treatment of active gastric ulcer (benign), maintenance of healing after gastric acid ulcer therapy (reduced dose) **Other conditions**: Treatment of GERD symptoms (symptoms usually improve within 24 hours), treatment of erosive esophagitis (endoscopically diagnosed) and maintenance of healing [FDA label] DB00863
21 Sulindac For acute or long-term use in the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute painful shoulder (acute subacromial bursitis/supraspinatus tendinitis), and acute gouty arthritis. DB00605
22 Tenoxicam For the treatment of rheumatoid arthritis, osteoarthritis, backache, and pain. DB00469
23 Tiaprofenic acid Tiaprofenic acid is used to treat pain, especially arthritic pain. DB01600
24 Tolmetin For the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis, including the treatment of acute flares long-term management. Also for treatment of juvenile rheumatoid arthritis. DB00500

Drugs for Osteoarthritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 658)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
2
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
3
Azithromycin Approved Phase 4 83905-01-5 447043 55185
4
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
5
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
6
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
7
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
8
Levomilnacipran Approved, Investigational Phase 4 96847-54-0
9
Aceclofenac Approved, Investigational Phase 4 89796-99-6
10
Aminocaproic acid Approved, Investigational Phase 4 60-32-2 564
11
Histamine Approved, Investigational Phase 4 51-45-6 774
12
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
13
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
14
Lumiracoxib Approved, Investigational Phase 4 220991-20-8 151166
15
Zinc Approved, Investigational Phase 4 7440-66-6 32051
16
Zoledronic Acid Approved Phase 4 118072-93-8 68740
17
Promethazine Approved, Investigational Phase 4 60-87-7 4927
18
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
19
Zolpidem Approved Phase 4 82626-48-0 5732
20
Rivaroxaban Approved Phase 4 366789-02-8
21
Enoxaparin Approved Phase 4 9005-49-6 772
22
Nabumetone Approved Phase 4 42924-53-8 4409
23
Ketoprofen Approved, Vet_approved Phase 4 22071-15-4 3825
24
Piroxicam Approved, Investigational Phase 4 36322-90-4 5280452 54676228
25
Denosumab Approved Phase 4 615258-40-7
26
Dalteparin Approved Phase 4 9005-49-6
27
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
28
Methylene blue Approved, Investigational Phase 4 61-73-4
29
Infliximab Approved Phase 4 170277-31-3
30
Hyoscyamine Approved Phase 4 101-31-5 64692
31
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
32
Zinc sulfate Approved, Investigational Phase 4 7733-02-0
33
Parecoxib Approved Phase 4 198470-84-7
34
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
35
Ticagrelor Approved Phase 4 274693-27-5 9871419
36
Rutin Approved, Experimental, Investigational Phase 4 153-18-4 5280805
37
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
38
Tranylcypromine Approved, Investigational Phase 4 155-09-9 441233
39
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
40
Amlodipine Approved Phase 4 88150-42-9 2162
41
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
42
Etidronic acid Approved Phase 4 2809-21-4, 7414-83-7 3305
43
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
44
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
45
Demeclocycline Approved Phase 4 127-33-3 5311063
46
Propranolol Approved, Investigational Phase 4 525-66-6 4946
47
Ergotamine Approved Phase 4 113-15-5 8223
48
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
49
Nortriptyline Approved Phase 4 72-69-5 4543
50
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795

Interventional clinical trials:

(show top 50) (show all 4233)
# Name Status NCT ID Phase Drugs
1 Efficacy of Intra-articular Injection of Combined Hyaluronic Acid and Platelet-rich Plasma in Knee Degenerative Joint Disease Unknown status NCT03211650 Phase 4 hyaluronic Acid + platelet-rich plasma;hyaluronic acid;platelet-rich plasma
2 Artelon MTP Spacer - Surgical Treatment of Mild to Moderate Hallux Rigidus Unknown status NCT01028469 Phase 4
3 Comparison Between Minimally Invasive Anterior Approach and Direct Lateral Approach in Total Hip Arthroplasty - A Prospective Randomized Trial Unknown status NCT01578746 Phase 4
4 Assessment of a Knee Brace in Patients With Osteoarthritis Unknown status NCT02706106 Phase 4
5 Intraarticular Xylitol Injections for Knee Osteoarthritis Unknown status NCT02104596 Phase 4
6 EVALUATION OF THE RELATIONSHIP BETWEEN EFFERVESCENT PARACETAMOL AND BLOOD PRESSURE. CLINICAL TRIAL. Unknown status NCT02514538 Phase 4 Non- effervescent Paracetamol kern;Effervescent paracetamol termalgin
7 A Multicenter,Open-label Phase Ⅳ Trial of Imrecoxib in Treatment of Knee Osteoarthritis Unknown status NCT01985165 Phase 4 Imrecoxib
8 Effect of Flex-a-New on Osteoarthritis of the Knee Unknown status NCT00294801 Phase 4 flex-a-new (food supplement)
9 A Double-Blind, Placebo-Controlled, Crossover Pilot Study of the Efficacy of Celecoxib 200 Mg Qd in Relieving Pain and Walking Dysfunction in Osteoarthritis of the Knee Unknown status NCT00194090 Phase 4 celecoxib
10 A Single-Blind Prospective Parallel Control Group Pilot Study to Assess the Effect of Hylan G-F 20 (Synvisc) Supplementation on Cartilage Preservation in Osteoarthritis of the Knee Unknown status NCT00393393 Phase 4 intra-articular injection of Hylan G-F 20
11 Prospective, Single Arm, Pilot Study Evaluating the Safety and Efficacy of Hyaluronan (Hylan GF-20) in Patients With Painful Shoulder Osteoarthritis Unknown status NCT00253799 Phase 4
12 Randomized, Double-blind, Placebo-controlled Study to Asses the Effect of Chondroitin Sulphate in Patients With Knee Osteoarthritis by Functional Magnetic Resonance Imaging Unknown status NCT01226615 Phase 4 Chondroitin sulphate (Condrosan®);Placebo
13 Double-blind, Randomised, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of the Combination of Chondroitin Sulphate and Glucosamine Hydrochloride in Patients With Hand Osteoarthritis Unknown status NCT02823548 Phase 4 Droglican;Placebo
14 Subclinical Joint Bleeding in Irish Adults With Severe Haemophilia A on Personalised Prophylaxis Regimens Unknown status NCT02314325 Phase 4 ADVATE [Antihemophilic Factor (Recombinant)];ADVATE [Antihemophilic Factor (Recombinant)]
15 Open-label, Multicenter, Randomized Study to Assess the Efficacy and Safety of Celecoxib 200mg Capsule QD and Celecoxib 100mg BID in Hand Osteoarthritis Patients Unknown status NCT03067194 Phase 4 Celecoxib 100 MG;Celecoxib 200mg
16 A Multicentre, Randomized, Double-blinded, Parallel-controlled, Non-inferiority Clinical Study Of Safety and Efficacy Of Medical Chitosan for Knee Osteoarthritis Compared With Sodium Hyaluronate Injection Unknown status NCT02323451 Phase 4 Sodium Hyaluronate Injection
17 Intra-Articular Injections of Hyaluronan Versus 20 Ml NaCl Versus Placebo in Treatment of Knee Osteoarthritis: a Randomised, Double-Blind, Placebo Controlled Single Centre Trial. Unknown status NCT00144820 Phase 4 Injection of Hyaluronan or Saline
18 Influence of Perception of Patients Suffering of Osteoarthritis of Knee Over the Effectiveness and Tolerance in Intra-articular Injection of Corticoids: a Prospective, Controlled and Randomized Study Unknown status NCT02835521 Phase 4 Joint injection with triamcinolone hexacetonide
19 Additional Therapeutic Effects of Dextrose to Hyaluronic Acid on Knee Osteoarthritis: a Double Blind, Randomized-controlled Clinical Trial Unknown status NCT03238183 Phase 4 dextrose
20 Additional Therapeutic Effects of Triamcinolone to Hyaluronic Acid on Knee Osteoarthritis: A Double Blind, Randomized-controlled Clinical Trial Unknown status NCT02949466 Phase 4 Triamcinolone
21 A Randomized, Double Blind, Single Simulation, Parallel Controlled, Multi-center Clinical Study of Guli Capsules in the Treatment of Knee Osteoarthritis Unknown status NCT02484508 Phase 4 Guli capsule;Kangguzengsheng capsule
22 Comparison of Therapeutic Effects of Hyaluronic Acid vs. Hyaluronic Acid Combined Corticosteroid on Knee Osteoarthritis: A Double Blind, Randomized-controlled Clinical Trial Unknown status NCT02625727 Phase 4
23 Effects of Perioperative Intravenous Dexamethasone on the Severity of Persistent Postsurgical Pain After Total Knee Arthroplasty : A Prospective, Randomized, Double-blind, Placebo-controlled Trial Unknown status NCT02760459 Phase 4 Dexamethasone;Normal saline solution
24 Investigating the Use of a Cryopneumatic Therapy Device in Primary Total Knee Arthroplasty Patients Unknown status NCT00712816 Phase 4
25 Comparing Clinical Outcome of 2 Different Total Knee Prostheses: Nexgen LPS-Flex and AGC Unknown status NCT00294528 Phase 4
26 Intra-articular Botulinum Toxin Type A Versus Corticosteroids: a Clinical Trial in Osteoarthritis of Knees Unknown status NCT02829281 Phase 4 Botulinum Toxin Type A;Triamcinolone hexacetonide;Saline
27 A 26 Week Multicenter Prospective Open Label Clinical Study Evaluating a Single Intra-articular Injection of DUROLANE SJ1ml for Treatment of OA Pain of the Ankle Unknown status NCT02627859 Phase 4
28 A Randomised Placebo Controlled Trial. The Effect of Spironolactone on Pain in Older People With Osteoarthritis Unknown status NCT02046668 Phase 4 spironolactone
29 Viscosupplementation in Patients With Severe Osteoarthritis of the Knee Unknown status NCT03090698 Phase 4 Hylan G-F 20;Triamcinolone
30 A Prospective, Randomized, Double-blinded, Double-dummy, Active-controlled, Multi-center, Interventional Study to Compare Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis Unknown status NCT02355236 Phase 4 Naproxen/Esomeprazol 500/20mg;Celecoxib 200mg;Naxozol-Placebo;Comparator-Placebo
31 Comparison of Outcomes in Mobile and Fixed-bearing Total Knee Arthroplasty Unknown status NCT01027819 Phase 4
32 The Biomechanical Impact of Intra-Articular Hyaluronic Acid in Knee Osteoarthritis Patients: A Randomized, Double Blind, Placebo Controlled Study Unknown status NCT00778076 Phase 4
33 A Prospective Randomized Control Trial to Compare the Aquamantys System With Standard Electrocautery in Reducing Blood Loss in Primary Total Knee Arthroplasty Unknown status NCT01736644 Phase 4
34 Comparison of Floseal® and Tranexamic Acid on Bleeding Control After Total Knee Arthroplasty - Randomized Prospective Study Unknown status NCT02152917 Phase 4 Tranexamic acid;Floseal®
35 Effectiveness of Trapeziometacarpal Splint Unknown status NCT02635932 Phase 4
36 A Double-Blind, Placebo-Controlled, Enriched Enrollment Randomized Withdrawal Study to Evaluate the Efficacy of Milnacipran in the Treatment of Pain Due to Osteoarthritis Unknown status NCT01329406 Phase 4 Milnacipran;Placebo
37 A Multi-center, Randomized, Open-label, Parallel-arm Controlled Study Comparing Demand-based Monotherapy of Non-steroidal Anti-inflammatory Drug (NSAID) vs. Demand-based NSAID Combined With Sodium Hyaluronate Injection in the Treatment of Chinese Patients With Mild to Moderate Knee Osteoarthritis Unknown status NCT02826031 Phase 4 Sodium Hyaluronate Injection;DICL-SR
38 Hip Viscosupplementation: What is the Best Dosage? Unknown status NCT01810809 Phase 4 1 ampoule of Hylan GF-20;2 ampoules of Hylan GF-20;3 ampoules of Hylan GF-20
39 The Effect of Glucosamine Sulphate on Structural Disease Progression in Knee Osteoarthritis and the Cost-effectiveness of Glucosamine Sulphate for Knee Arthritis. Unknown status NCT00513422 Phase 4
40 The Effect of Intraaricular Knee Injections of Hyaluronic Acid (HA) on Bone and Cartilaginous Debris, as a Therapeutic Indicator Unknown status NCT00422643 Phase 4 Sodium hyaluronate (hyaluronic acid)
41 Phase IV Study - Prophecy Guide Outcomes in Total Knee Replacement Surgery Unknown status NCT01163708 Phase 4
42 The Effects of Tourniquet Reinflation After Early Tourniquet Release in Total Knee Arthroplasty Unknown status NCT01832272 Phase 4
43 Chondroitin Sulphate Treatment Efficacy in Rhizarthrosis. Measurement With Sensory and Quantitive Functional Tests and Concordance Analysis With Subjective Scales of Pain. Unknown status NCT01233739 Phase 4 Chondroitin sulfate;Placebo
44 Open Label Study of Prednisone and Azithromycin in the Treatment of Patients With Cat Scratch Disease Unknown status NCT01469702 Phase 4 prednison and azithromycin;prednison, azithromycin;prednison, Azenil
45 Bone Forming at Prosthetic Surfaces. A Randomized Clinical F-PET/CT Study Unknown status NCT01623687 Phase 4
46 Effectiveness of Intraoperative Exparel, a Bupivacaine Liposome Injectable Suspension, for Postoperative Pain Control in Total Knee Arthroplasty: A Prospective, Randomized, Double Blind, Controlled Study Unknown status NCT02808728 Phase 4 Pain Cocktail with Exparel;Pain Cocktail with Ropivacaine
47 Prospective, Randomized, Double-Blinded, Allocation Concealed Study Comparing the Efficacy of Liposomal Bupivacaine Over Standard Bupivacaine Plus Dexamethasone in Quadriceps Sparing Femoral Nerve Block and Wound Infiltration for Primary Total Knee Arthroplasty Unknown status NCT02624856 Phase 4 Liposomal bupivacaine;Bupivacaine plus dexamethasone
48 A Post-marketing Surveillance to Evaluate the Efficacy and Safety of CHONDRON (Autologous Cultured Chondrocyte) Through Arthroscopy in Patients With Knee Cartilage Defects Unknown status NCT02539069 Phase 4
49 This Post-marketing Surveillance to Evaluate the Efficacy and Safety of a CHONDRON (Autologous Cultured Chondrocyte) in Patients With Cartilage Defects in Their Knees. Unknown status NCT02539056 Phase 4
50 Outcome Comparison of Allogenic Cancellous Bone and a New Synthetic Bone Substitute (geneX®) in Filling the Bone Defect Created With Medial Open Wedge High Tibial Osteotomy Unknown status NCT02000297 Phase 4

Search NIH Clinical Center for Osteoarthritis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


ACETYLSALICYLATE SODIUM
Aspirin
ASPIRIN PWDR
Bupivacaine
celecoxib
Celecoxib
Choline magnesium trisalicylate
choline salicylate
Chondroitin
CHONDROITIN SODIUM
Chondroitin Sulfates
Diclofenac
Diclofenac
Diclofenac Potassium
Diclofenac Sodium
Diflunisal
Diflunisal
Duloxetine
Etodolac
Etodolac
Fenoprofen
Fenoprofen
Fenoprofen Calcium
Flurbiprofen
Flurbiprofen
Flurbiprofen sodium
Glucosamine
HYLAN G-F 20
Ibuprofen
Ibuprofen
Indomethacin
Indomethacin
INDOMETHACIN PWDR
INDOMETHACIN SODIUM
Ketoprofen
Ketoprofen
KETOPROFEN PWDR
Meclofenamic acid
meloxicam
Meloxicam
nabumetone
Nabumetone
Naproxen
Naproxen
Naproxen sodium
Ox bile extract
oxaprozin
Oxaprozin
Piroxicam
Piroxicam
Ranitidine
rofecoxib
solufenum
Sulindac
Sulindac
Tenoxicam
Tiaprofenic acid
Tolmetin
Tolmetin
Tolmetin Sodium
valdecoxib

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Osteoarthritis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Osteoarthritis:
4D20.8 PureStem-derived chondrocytes for treatment of osteochondral defects
AlloStem, adipose-derived mesenchymal stem cells combined with allograft bone for bone grafting
Autologous adipose-derived mesenchymal stromal cells for the treatment of osteoarthritis
Autologous bone marrow-derived stem cells for the treatment of osteoarthritis
Autologous chondrocyte for severe hip osteoarthritis
Bone marrow-derived mesenchymal stem cells for osteoarthritis
Bone marrow-derived mesenchymal stem cells for knee osteoarthritis
Bone marrow-derived mesenchymal stem cells for knee osteoarthritis
Bone marrow-derived stem cells for knee osteoarthritis
Carticel, autologous cultured chondrocytes for treatment of cartilage defects
CARTISTEM, mesenchymal stem cells for treatment of osteoarthritis
Chondrocell, bone marrow-derived mesenchymal stem cells for osteoarthritis
Chondrogen, mesenchymal stem cells for meniscus regeneration and knee osteoarthritis prevention
HiQCell, adipose-derived stromal vascular fraction for osteoarthritis
JACC, cultured cartilage for chondral lesion
Mesenchymal stem cell for meniscal regeneration after hemi-meniscectomy
ReJoin(TM), adipose-derived mesenchymal precursor cell for knee osteoarthritis
RNL-JointStem, adipose-derived mesenchymal stem cells for degenerative arthritis
StempeucelOA, mesenchymal stem cells for treatment of osteoarthritis
Trinity Evolution, mesenchymal stem cells with osteoprogenitors for musculoskeletal defects
Embryonic/Adult Cultured Cells Related to Osteoarthritis:
PureStem 4D20.8, NCr-fac Progenitor PMIDs: 22519755
Adipose-derived mesenchymal stem cells combined with allograft bone (AlloStem) PMIDs: 22500696
Adipose-derived mesenchymal stromal cells PMIDs: 23613363
Bone marrow-derived mesenchymal stem cells
Bone marrow-derived mesenchymal stromal cells
Chondrocytes (Carticel) PMIDs: 17515233 17590152 16510814
Bone marrow-derived mesenchymal stem cells (family)
Bone marrow-derived mesenchymal stem cells PMIDs: 12708651 19530993 14673997 10102814
Adipose-derived stromal vascular fraction and adipocytes (HiQCell) PMIDs: 22913454
Cultured cartilage (JACC) PMIDs: 19393556 10738867 16226641 12043781 16233853 19802670 10679677 11284883 16233778
Bone marrow-derived mesenchymal stem cells PMIDs: 22750747
Bone marrow-derived mesenchymal stem cells PMIDs: 22750747
Adipose-derived mesenchymal stem cells (family)
Adipose-derived mesenchymal stem cells PMIDs: 21303266 24341080
Bone marrow-derived mesenchymal stem cells (Stempeucel) PMIDs: 22837175
Demineralized bone with osteoprogenitor and adult stem cells (Trinity Evolution) PMIDs: 20508015 21056860

Cochrane evidence based reviews: osteoarthritis

Genetic Tests for Osteoarthritis

Genetic tests related to Osteoarthritis:

# Genetic test Affiliating Genes
1 Osteoarthritis 29 FRZB

Anatomical Context for Osteoarthritis

MalaCards organs/tissues related to Osteoarthritis:

41
Bone, Testes, Bone Marrow, Brain, Endothelial, Skin, T Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Osteoarthritis:

19
Joint
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Osteoarthritis:
# Tissue Anatomical CompartmentCell Relevance
1 Cartilage Temporomandibular Joint Affected by disease
2 Bone Vertebrae Affected by disease
3 Cartilage Autopod Articular Cartilage Articular Cartilage Cells Affected by disease
4 Cartilage Zeugopod Articular Cartilage Articular Cartilage Cells Affected by disease
5 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
6 Limb Zeugopod Synovial Joint Central Intermediate Lamina Cells Affected by disease
7 Limb Autopod Synovial Joint Central Intermediate Lamina Cells Affected by disease
8 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
9 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate

Publications for Osteoarthritis

Articles related to Osteoarthritis:

(show top 50) (show all 33652)
# Title Authors PMID Year
1
Functional variants within the secreted frizzled-related protein 3 gene are associated with hip osteoarthritis in females. 38 71
15210948 2004
2
Can spinopelvic mobility be predicted in patients awaiting total hip arthroplasty? A prospective, diagnostic study of patients with end-stage hip osteoarthritis. 38 17
31362559 2019
3
A randomized controlled trial of tibial component migration with kinematic alignment using patient-specific instrumentation versus mechanical alignment using computer-assisted surgery in total knee arthroplasty. 17
31362561 2019
4
Classification of combined partial knee arthroplasty. 17
31362558 2019
5
Transcriptional regulation of endochondral ossification by HIF-2alpha during skeletal growth and osteoarthritis development. 9 38
20495570 2010
6
Serum transforming growth factor-beta 1 is not a robust biomarker of incident and progressive radiographic osteoarthritis at the hip and knee: the Johnston County Osteoarthritis Project. 9 38
20206313 2010
7
A COL2A1 gene polymorphism is related with advanced stages of osteoarthritis of the knee in Mexican Mestizo population. 9 38
19756630 2010
8
Phytoestrogen bavachin mediates anti-inflammation targeting Ikappa B kinase-I kappaB alpha-NF-kappaB signaling pathway in chondrocytes in vitro. 9 38
20361957 2010
9
A meta-analysis of interleukin-6 promoter polymorphisms on risk of hip and knee osteoarthritis. 9 38
20175976 2010
10
MicroRNA-27b regulates the expression of matrix metalloproteinase 13 in human osteoarthritis chondrocytes. 9 38
20131257 2010
11
Novel selective MMP-13 inhibitors reduce collagen degradation in bovine articular and human osteoarthritis cartilage explants. 9 38
19902332 2010
12
Hyaluronic acid modulates gene expression of connective tissue growth factor (CTGF), transforming growth factor-beta1 (TGF-beta1), and vascular endothelial growth factor (VEGF) in human fibroblast-like synovial cells from advanced-stage osteoarthritis in vitro. 9 38
19890996 2010
13
[Expressions of interleukin 18 and prostaglandin E2 and their correlation in the synoviocytes of patients with osteoarthritis]. 9 38
20423837 2010
14
Changes in content and synthesis of collagen types and proteoglycans in osteoarthritis of the knee joint and comparison of quantitative analysis with Photoshop-based image analysis. 9 38
19838720 2010
15
High specificity but low sensitivity of the cartilage oligomeric matrix protein (COMP) test in rheumatoid arthritis and osteoarthritis. 9 38
20148721 2010
16
Interleukin-1 gene cluster variants with innate cytokine production profiles and osteoarthritis in subjects from the Genetics, Osteoarthritis and Progression Study. 9 38
20131253 2010
17
A matrilin-3 mutation associated with osteoarthritis does not affect collagen affinity but promotes the formation of wider cartilage collagen fibrils. 9 38
20077500 2010
18
The genetic epidemiology of osteoarthritis. 9 38
20090528 2010
19
Low-density lipoprotein receptor-related protein 5 (LRP5) expression in human osteoarthritic chondrocytes. 9 38
19810105 2010
20
Nonsteroidal antiinflammatory drugs and prostaglandin E(2) modulate the synthesis of osteoprotegerin and RANKL in the cartilage of patients with severe knee osteoarthritis. 9 38
20112374 2010
21
[Detection of bone erosions in knee osteoarthrosis by serum biomarkers]. 9 38
20422912 2010
22
The transcript level of interleukin-6 in the cartilage of idiopathic osteoarthritis of knee. 9 38
20393674 2010
23
Glucosamine but not ibuprofen alters cartilage turnover in osteoarthritis patients in response to physical training. 9 38
19679221 2010
24
Modulating hedgehog signaling can attenuate the severity of osteoarthritis. 9 38
19915594 2009
25
Association of a functional microsatellite within intron 1 of the BMP5 gene with susceptibility to osteoarthritis. 9 38
20021689 2009
26
Modulation of OPG, RANK and RANKL by human chondrocytes and their implication during osteoarthritis. 9 38
19762475 2009
27
Association of the DVWA and GDF5 polymorphisms with osteoarthritis in UK populations. 9 38
19054821 2009
28
Whole-body bone scintigraphy provides a measure of the total-body burden of osteoarthritis for the purpose of systemic biomarker validation. 9 38
19877068 2009
29
Genetic variation in the GDF5 region is associated with osteoarthritis, height, hip axis length and fracture risk: the Rotterdam study. 9 38
19029166 2009
30
Asporin and transforming growth factor-beta gene expression in osteoblasts from subchondral bone and osteophytes in osteoarthritis. 9 38
19997821 2009
31
Elevated circulating and synovial fluid endoglin are associated with primary knee osteoarthritis severity. 9 38
20082874 2009
32
COL2A1 gene polymorphisms and susceptibility to osteoarthritis of the hand in Finnish women. 9 38
19019890 2009
33
Expression and activity of COX-1 and 2 and 5-LOX in joint tissues from dogs with naturally occurring coxofemoral joint osteoarthritis. 9 38
19274754 2009
34
Syndecan-4 regulates ADAMTS-5 activation and cartilage breakdown in osteoarthritis. 9 38
19684582 2009
35
Local and systemic activation of the mononuclear phagocyte system in aseptic loosening of total hip arthroplasty. 9 38
19536644 2009
36
N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis. 9 38
19606871 2009
37
Missense single nucleotide polymorphism of the ADAM12 gene is associated with radiographic knee osteoarthritis in middle-aged Estonian cohort. 9 38
19268722 2009
38
Phellodendron and Citrus extracts benefit joint health in osteoarthritis patients: a pilot, double-blind, placebo-controlled study. 9 38
19682376 2009
39
Fibroblast growth factor 2: A new key player in osteoarthritis. 9 38
19565484 2009
40
Functional analysis of the osteoarthritis susceptibility-associated GDF5 regulatory polymorphism. 9 38
19565498 2009
41
Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis. 9 38
19602530 2009
42
A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models. 9 38
19565489 2009
43
Global analysis of nuclear receptor expression and dysregulation in human osteoarthritic articular cartilage: reduced LXR signaling contributes to catabolic metabolism typical of osteoarthritis. 9 38
19217805 2009
44
[Effect of electroacupuncture on the level of IL-1beta and TNF-alpha in patients with osteoarthritis]. 9 38
19835118 2009
45
The knee osteoarthritis susceptibility locus DVWA on chromosome 3p24.3 is the 5' part of the split COL6A4 gene. 9 38
19486942 2009
46
Fibroblast growth factor 2 is an intrinsic chondroprotective agent that suppresses ADAMTS-5 and delays cartilage degradation in murine osteoarthritis. 9 38
19565481 2009
47
Pretreatment insulin-like growth factor-I concentrations predict radiographic osteoarthritis in acromegalic patients with long-term cured disease. 9 38
19366851 2009
48
Selective MMP-12 inhibitors: WO-2008057254. 9 38
19456279 2009
49
Failure of serum transforming growth factor-beta (TGF-beta1) as a biomarker of radiographic osteoarthritis at the knee and hip: a cross-sectional analysis in the Johnston County Osteoarthritis Project. 9 38
19091605 2009
50
Large-scale analysis of association between GDF5 and FRZB variants and osteoarthritis of the hip, knee, and hand. 9 38
19479880 2009